Date: 2015-08-03
Type of information: Company acquisition
Acquired company: 51% equity share of Immuneering Corporation (USA - MA)
Acquiring company: Teva Pharmaceutical (Israel)
Amount: undisclosed
Terms: * On August 3, 2015, Teva Pharmaceutical and Immuneering Corporation announced that the companies have entered into an agreement in which Teva will purchase a 51% equity share of the genomic-analysis company. Teva\'s majority holding in Immuneering provides right of first refusal in projects relating to the Company\'s stated objective of developing, personalizing and improving treatment of disorders of the Central Nervous System (CNS).
Details: Immuneering uses advanced proprietary techniques to identify hidden signals and biological insights across an array of genetic, genomic, and proteomic data that can direct research for enhanced discovery, development and clinical success. Teva and Immuneering have worked together over the past several years to unlock significant findings into genetic biomarkers, therapy-specific gene expression signatures and breakthrough work in characterizing non-biological complex drugs (NBCDs).
Related: Technology - Services Biomarkers
